GLP-1 Provider Q&A: Trimi Physicians Answer

A: For most new patients, we start with semaglutide. It has the longest safety track record, proven cardiovascular benefits from the SELECT trial, and at $99/month it is the most affordable option. If a patient has significant weight to lose (BMI 35+), has type 2 diabetes that needs aggressive management, or has tried semaglutide previously without adequate response, we may start with tirzepatide at $125/month. The beauty of Trimi offering all three medications is that we can always adjust based on how the patient responds.

A: Retatrutide is our most potent option, but it is still investigational. We generally reserve it for patients who have tried semaglutide and/or tirzepatide without achieving their goals, patients with BMI 40+ who need maximum efficacy, or patients with concurrent MASH/NAFLD where the dramatic liver fat reduction is particularly beneficial. We have a thorough informed consent process given its pre-approval status, and we monitor these patients more closely.

A: The GI side effects that make patients quit are almost always from titrating too fast. The standard 4-week-per-step protocol is the minimum. I often keep patients at a dose for 6-8 weeks if they are still experiencing nausea. There is no rush. A patient who reaches 2.4mg of semaglutide comfortably at month 6 will have better outcomes than one who races there by month 3 but quits from intolerable nausea.

A: Absolutely not. If a patient is losing weight consistently at 1.7mg semaglutide or 10mg tirzepatide with minimal side effects, there may be no reason to increase further. The right dose is the lowest effective dose for each individual patient. Some of our best outcomes are patients on moderate doses who maintain excellent adherence because they feel good.

A: Step one is dietary modification: smaller meals, low-fat foods, adequate hydration. Step two is holding the current dose for an additional 4 weeks rather than escalating. Step three, if nausea persists beyond 6-8 weeks at a stable dose, we consider whether a medication switch might help. Some patients tolerate tirzepatide better than semaglutide, or vice versa. We rarely need to prescribe anti-nausea medication, but it is an option for severe cases.

A: This is one of our most important patient education topics. Every patient starting GLP-1 therapy gets our protein and exercise guidance. We recommend 1.0-1.2g protein per kilogram of body weight minimum, resistance training 2-3 times weekly, and we track body composition when possible -- not just scale weight. The data is clear that patients who combine GLP-1 with strength training lose primarily fat while preserving lean mass.

A: We exclusively work with FDA-registered 503B outsourcing facilities that follow current Good Manufacturing Practices. Every batch comes with a certificate of analysis confirming potency, sterility, and endotoxin testing. We verify pharmacy registrations regularly. The active ingredient in our compounded semaglutide is identical to what is in Wegovy -- the difference is the delivery system and the price tag. Our patients get excellent results at $99/month that are clinically indistinguishable from $1,350/month brand-name.

A: The honest answer is: most do, at some level. The data clearly shows that stopping leads to weight regain in the majority of patients. However, many patients can reduce to a lower maintenance dose. Some transition from a more expensive medication to a less expensive one -- for example, losing weight on tirzepatide and maintaining on semaglutide at $125/month. A small percentage successfully maintain weight loss after stopping through rigorous lifestyle habits, but this is the exception, not the rule. We support patients wherever they are on this spectrum.

A: Baseline labs before starting, then at 3, 6, and 12 months. We check metabolic panel, lipid panel, HbA1c, liver function, thyroid, vitamin D, and B12 at minimum. For patients on retatrutide, we add more frequent liver function monitoring. For patients losing large amounts of weight, we include a comprehensive nutrient panel. Regular monitoring catches potential issues early and lets us document the incredible metabolic improvements most patients experience.